Abstract
Introduction
nasal washing was performed. These lavages were analyzed to evaluate the kinetics of 
Lipopolysaccharide (LPS) detection

184
To exclude the possibility of LPS contamination, the Limulus amebocyte lysate test 185 using the Gel-clot method (Pyrotell) was performed for culture supernatants and were pretreated with macrolides for 24 hours (the ratio bacteria : macrophage = 25:1).
209
Peritoneal macrophages and pneumococcus were co-cultured for 45 minutes at 37 °C 210 under 5% CO2 in humidified air. Phagocytosis was stopped by putting the plates on ice,
211
following adherent bacteria were removed by washing cells with PBS. To quantify
Western blotting
215
Cells were washed and lysed for 5 min in RIPA buffer (Sigma-Aldrich Japan, Tokyo, 216 Japan) containing protease inhibitor cocktail (Sigma-Aldrich Japan, Tokyo, Japan), and 217 the protein concentration was determined using the bicinchoninic acid protein assay kit 
Statistical analyses
240
All data were analyzed by using Prism 5 GraphPad Software and are expressed as the 241 mean ± SEM. Differences between the treatment group and the control were tested for 242 significance using the Mann-Whitney U test. The significance of differences among 243 more than three groups was examined using ANOVA followed by Dunnett's or
244
Turkey's post-tests. Survival analysis was performed using the log-rank test, and 245 survival rates were calculated via the Kaplan-Meier method. P < 0.05 was considered 246 statistically significant. 
Results
249
The effect of EM900 on pneumococcal nasopharyngeal colonization 250 To examine the importance of immunomodulation in regulating pneumococcal 251 colonization, EM900, a novel 12-membered non-antibiotic macrolide that has an 252 immunomodulatory effect, was administered 7 days prior to S. pneumoniae inoculation 253 and continued throughout the observational period. As shown in Figure 1A , the density 254 of pneumococcus in the URT was significantly decreased in EM900-treated mice 255 compared to untreated mice 14 days after pneumococcal inoculation. FACS analysis of 256 nasal lavages was performed to measure the number of inflammatory cells recruited to 257 the URT at 7 and 14 days after pneumococcal inoculation (Fig. 1B, 1C ). The number of 258 macrophages in the URT was significantly higher in EM900-treated mice than in 259 untreated mice 14 days after pneumococcal inoculation. These data indicate that EM900 260 promoted macrophage recruitment to the URT and reduced pneumococcal colonization 261 in a macrophage-dependent manner through its immunomodulatory effects. (Fig. 4B) . Furthermore, when production of numerous cytokines was 295 screened by cytokine array, it was observed that while CCL2 production was clearly 296 present, pro-inflammatory cytokines associated with tissue injury such as TNF-α were 297 not ( Supplementary Fig. 1 ).
298
To determine the effect of macrolides on the phagocytic function of macrophages, we To investigate the role of macrophage recruitment in priming innate immunity, we 326 challenged mice with the P1547 (serotype 6A) and P173 (serotype 2) strains, and 327 treated them with EM900. We found that EM900-treated mice were more resistant to 328 sepsis than untreated mice ( Fig. 7A and 7B) , which suggests that a reduction in the 
343
Our results demonstrated that the extent of bacterial colonization 14 days after 344 bacterial inoculation was significantly decreased compared to that in the control group.
345
There was also a significant increase in the number of nasopharyngeal macrophages in showed that the survival rate was improved significantly in the EM900 pre-administered 360 group compared to the non-administered group. The increase in CCL2 production was 361 observed even with frequently used macrolides, e.g., CAM and AZM, suggesting that reported increased CCL2 production without any effect on IL-6 and TNF-α expression 373 after pre-administration of azithromycin in monocytes that had been activated with IFN-γ and LPS [23] . In this study, to evaluate the production of other inflammatory 375 cytokines, the culture supernatant of macrophages treated with macrolides was profiled 376 using cytokine arrays. CCL2 production was markedly increased; however, increased 377 production of inflammatory cytokines associated with tissue damage such as TNF-α was 378 not observed (Supplemental Figure 1) . Additionally, when intraperitoneal macrophages 379 were stimulated in the same way by ampicillin (a cell wall synthesis inhibitor), 380 increased CCL2 production was not observed (data not shown). From the above results,
381
we conclude that the promotion of CCL2 production was specific to macrolides and had 382 a protective effect on the host.
383
Next, to clarify the mechanism by which CCL2 production was increased by 384 macrolide treatment, analysis of several intracellular signal transduction pathways was 385 performed using RNA interference. We found that EM900, CAM, and AZM induced 386 CCL2 production, dependent on NF-κB, and was shown to act on both MyD88 and 387 TRIF, which are adaptor proteins upstream of the NF-κB pathway. Shinkai et al. 
